US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

1.76

-0.0350-1.96%

Volume:68.13K

Turnover:120.63K

Market Cap:202.29M

PE:-2.54

High:1.82

Open:1.79

Low:1.76

Close:1.79

52wk High:6.79

52wk Low:1.46

Shares:115.27M

Float Shares:64.56M

Volume Ratio:0.31

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6900

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:1.01

PE(LYR):-1.90

Loading ...

Overview Company News Filings

NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs

NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue

Novabridge Reports Full Year 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement

NovaBridge Biosciences expected to post a loss of 5 cents a share - Earnings Preview

NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement

NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement

NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement

NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement

NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong

NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang

NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Novabridge Biosciences: FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway

THOMSON REUTERS

Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026

THOMSON REUTERS

BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer

Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

THOMSON REUTERS

Novabridge Biosciences - FDA Confirms Givastomig Eligible for Accelerated Approval Pathway

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/NBP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":1.755,"timestamp":1788460579715,"preClose":1.79,"halted":0,"volume":68130,"delay":0,"changeRate":-0.019553072625698404,"floatShares":64563600,"shares":115266053,"eps":-0.69,"marketStatus":"Trading","change":-0.035,"latestTime":"09-03 14:38:27 EDT","open":1.79,"high":1.815,"low":1.755,"amount":120629.090799,"amplitude":0.03352,"askPrice":1.76,"askSize":696,"bidPrice":1.75,"bidSize":2265,"shortable":3,"etf":0,"ttmEps":-0.69,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.79,"preHourTrading":{"tag":"盘前","latestPrice":1.79,"preClose":1.79,"latestTime":"09:29 EDT","volume":648,"amount":1161.8299152,"timestamp":1788442199912,"change":0,"changeRate":0,"amplitude":0.01676},"postHourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.79,"latestTime":"19:30 EDT","volume":300,"amount":540.09,"timestamp":1788391805629,"change":0.03,"changeRate":0.01676,"amplitude":0.01676},"volumeRatio":0.309035,"impliedVol":1.8929,"impliedVolPercentile":0.7736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":0.309035,"shares":115266053,"dividePrice":0,"high":1.815,"amplitude":0.03352,"preClose":1.79,"low":1.755,"week52Low":1.46,"pbRate":"1.01","week52High":6.79,"institutionHeld":0,"latestPrice":1.755,"committee":0.529889,"eps":-0.69,"divideRate":0,"volume":68130,"delay":0,"ttmEps":-0.69,"open":1.79,"prevYearClose":3.98,"prevWeekClose":1.84,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.89,"twentyDayClose":1.7,"sixtyDayClose":1.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-09-02","current":-2.594203,"percent":1,"low":-20.276437,"twenty":-14.513199,"median":-10.607129,"eighty":-2.317159,"high":-1.707119,"avg":-8.423465,"sd":6.080639,"marketCap":200678643},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-09-02","current":-1.707119,"twenty":-14.513199,"median":-10.607129,"eighty":-2.317159,"marketCap":200678643}],"updateTime":1788429732451},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625961863","title":"NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625961863","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625961863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 05:21","pubTimestamp":1775596905,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences ( ($NBP) ) has issued an update. On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696988","title":"NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696988","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696988?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595030,"startTime":"0","endTime":"0","summary":"NovaBridge posted a net loss of USD 88.3 million for fiscal year 2025, widening from USD 22.2 million a year earlier.Revenue was unchanged at no revenue, versus USD 632,000 in 2023.Operating loss widened to USD 94.3 million as research and development expenses more than doubled to USD 62.9 million.Cash and cash equivalents totaled USD 210.6 million at year-end, with net cash used in operating activities of USD 20.6 million.NovaBridge forecast cash, cash equivalents and short-term investments of USD 210.8 million will fund operations into Q4 2028, while highlighting givastomig Phase 2 first-patient enrollment and plans to start a registrational Phase 3 trial as early as Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL2vRNKr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966041","title":"Novabridge Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966041?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUARHQZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625969836","title":"Press Release: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2625969836","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625969836?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595000,"startTime":"0","endTime":"0","summary":"-- Successful transformation to global biotech platform with two mid-stage. and durable responses with broad CLDN18.2 activity, favorable safety, as. well as potential eligibility for FDA's Accelerated Approval Pathway with. potential initiation of a registrational Phase 3 trial as early as Q4. produced rapid, robust and durable responses in treatment nave. wet-AMD patients, and is poised to begin Phase 2b studies in H2 2026. \"Compelling clinical results from the last quarter have reinforced the class-leading potential for givastomig and VIS-101 and meaningfully de-risked their clinical paths forward. For givastomig, the FDA confirmed potential eligibility for an Accelerated Approval pathway at a productive Type B meeting, following robust potential best-in-class Phase 1b efficacy and favorable overall tolerability results. At the same time, VIS-101 continues to advance in wet AMD following its successful Phase 2a readout showing rapid, robust, durable and potential best-in-class respo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU2089985449.USD","LU1880398471.USD","LU0390134368.USD","LU0823434583.USD","LU2250418816.HKD","LU0198837287.USD","BK4534","BK4614","BK4588","LU0823421416.USD","LU0274383776.USD","LU1303367103.USD","AMDU","BK4585","LU1989764664.SGD","BK4141","LU1242518931.SGD","LU1852331112.SGD","IE0004445239.USD","LU0889565833.HKD","LU2098885051.SGD","AMDD","BK4543","LU1951200564.SGD","LU0127658192.USD","LU0109392836.USD","LU1861558580.USD","BK4532","LU1316542783.SGD","LU2458330169.SGD","IE0009356076.USD","IE00BMPRXN33.USD","LU2355687059.USD","LU2458330243.SGD","NBP","LU0823434740.USD","AMDW","BK4512","LU0081259029.USD","LU1242518857.USD","LU0719512351.SGD","LU0979878070.USD","LU0642271901.SGD","BK4573","LU1923623000.USD","LU1988902786.USD","IE00BMPRXR70.SGD","LU1880398554.USD","AMYY","LU1803068979.SGD","DAMD","LU2054465674.USD","BK4612","LU0082616367.USD","BK4139","GFS","LU1064131342.USD","AMDY","LU2264538146.SGD","LU1951198990.SGD","AMDG","BK4554","AMUU","AMDL","LU2360106780.USD","BK4566","LU0823421333.USD","BK4529","LU0056508442.USD","BK4575","LU2931357623.SGD","IE00B5949003.HKD","BK4605"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624859416","title":"NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624859416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624859416?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:12","pubTimestamp":1775038347,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences director Conor Chia-hung Yang reported employee share options covering 148,623 ADSs, per an initial beneficial ownership filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4cmpmr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623262293","title":"NovaBridge Biosciences  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2623262293","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623262293?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:03","pubTimestamp":1774900988,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences  expected to post a loss of5cents a share - Earnings Preview NovaBridge Biosciences NBP.OQ NBP.O is expected to  show no change in quarterly revenue when it reports  results on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL8N40I1WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622144080","title":"NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622144080","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622144080?lang=en_us&edition=fundamental","pubTime":"2026-03-25 08:08","pubTimestamp":1774397339,"startTime":"0","endTime":"0","summary":"NovaBridge reported that Chu Denny Hsueh Wen, EVP and Head of Strategic Partnership, filed an initial Form 3 statement of beneficial ownership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2SZ0NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292194","title":"NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292194?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:45","pubTimestamp":1773884729,"startTime":"0","endTime":"0","summary":"Lorraine Lin Liwei filed an initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026.She is listed as an officer with the title of General Counsel.The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL73tVz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292918","title":"NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292918","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292918?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:44","pubTimestamp":1773884694,"startTime":"0","endTime":"0","summary":"Xi-Yong Fu filed an initial statement of beneficial ownership for NovaBridge Biosciences and is listed as Chief Executive Officer and Director.The filing reported 59,823 ordinary shares beneficially owned directly.It also reported employee share options covering 1.25 million ordinary shares at an exercise price of USD 1.07.Restricted share units covering 1.25 million ordinary shares were also reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL5tXpmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292538","title":"NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292538","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292538?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884205,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Emmett Cunningham filed an initial statement of beneficial ownership as a director. The filing disclosed a 2025 employee share option covering 120,000 shares with an exercise price of USD 3.21. The option has an expiration date of Feb. 17, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL275g0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620925802","title":"NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620925802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620925802?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884166,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Claire Xu Cong filed an initial statement of beneficial ownership as an officer. The filing lists her role as Senior Vice President, Clinical Development. Claire Xu Cong reported direct ownership of 288,266 ordinary shares. She also reported employee share options covering 22,900 ADSs at an exercise price of USD 61 and 43,690 ADSs at an exercise price of USD 21.15. The filing also reported restricted share units for 36,716 ADSs and 5,405 ADSs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3q83cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292872","title":"NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292872","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292872?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:32","pubTimestamp":1773883953,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Adeline Yi Zhang filed an initial statement of beneficial ownership. Zhang is listed as an officer with the title Global Controller. The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Q8VK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942702","title":"NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942702","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942702?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:25","pubTimestamp":1773883528,"startTime":"0","endTime":"0","summary":"Alan Au Chun Kwok filed a Form 3 initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026. The filing identifies Au as a director. Au reported a 2024 employee share option for 114,093 shares with an exercise price of USD 1.22. Au also reported a 2025 employee share option for 34,530 shares with an exercise price of USD 3.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Wzn3S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620467727","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620467727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620467727?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:30 ET (16:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619546825","title":"Novabridge Biosciences:  FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619546825?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619346826","title":"Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619346826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619346826?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450803","title":"BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450803","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450803?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:36","pubTimestamp":1773660985,"startTime":"0","endTime":"0","summary":"BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric CancerMarch 16 (Reuters) - NovaBridge Biosciences NBP.O:NOVABRIDGE ANNOUNCE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619524784","title":"NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619524784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619524784?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:04","pubTimestamp":1773659054,"startTime":"0","endTime":"0","summary":"NovaBridge reported that the FDA provided alignment in a Type B meeting on the potential eligibility of givastomig for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer. The company said the pathway would be supported by a registrational Phase 3 combination trial using objective response rate as a primary endpoint, which it expects to start as early as Q4 2026. NovaBridge stated that the accelerated approval discussions build on results from a Phase 1b combination trial that have already been presented. Phillip Dennis, Chief Medical Officer, said the company plans to continue discussions with the FDA on final Phase 3 study design details.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7DSH1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","NBP","BK4588","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619683452","title":"Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619683452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619683452?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619521804","title":"Novabridge Biosciences - FDA Confirms Givastomig Eligible for Accelerated Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2619521804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619521804?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":71,"code":"91000000","status":"200"}]}}